{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:20:23Z","timestamp":1774362023350,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.bone.2016.01.011","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T01:04:20Z","timestamp":1453338260000},"page":"55-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria"],"prefix":"10.1016","volume":"85","author":[{"given":"Phillip","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevan","family":"Polkinghorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.G.","family":"Doery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2444-3995","authenticated-orcid":false,"given":"I.","family":"Larmour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald K.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Milat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2016.01.011_bb0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2001.03195.x","article-title":"Practical management of iron overload","volume":"115","author":"Porter","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2016.01.011_bb0010","article-title":"Thalassemia bone disease: a 19year longitudinal analysis","volume":"25","author":"Wong","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.01.011_bb0015","series-title":"Osteoporosis International: A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","first-page":"1965","article-title":"Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures","volume":"24","author":"Wong","year":"2013"},{"key":"10.1016\/j.bone.2016.01.011_bb0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jbmr.522","article-title":"A case of hypophosphatemic osteomalacia secondary to deferasirox therapy","volume":"27","author":"Milat","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.01.011_bb0025","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.clinthera.2007.05.007","article-title":"Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with \u03b2-thalassemia","volume":"29","author":"Cappellini","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2016.01.011_bb0030","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"Aphase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with \u03b2-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.01.011_bb0035","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1600-0609.2009.01228.x","article-title":"Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with \u03b2-thalassaemia: the ESCALATOR study","volume":"82","author":"Taher","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2016.01.011_bb0040","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","article-title":"Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5years follow-up","volume":"118","author":"Cappellini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.01.011_bb0045","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2141.2009.07908.x","article-title":"Efficacy and safety of deferasirox doses of >30mg\/kg per d in patients with transfusion-dependent anaemia and iron overload","volume":"147","author":"Taher","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2016.01.011_bb0050","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/08880018.2013.823470","article-title":"A prospective study of tubular dysfunction in pediatric patients with beta thalassemia major receiving deferasirox","volume":"30","author":"Naderi","year":"2013","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2016.01.011_bb0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00277-012-1558-3","article-title":"Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience","volume":"92","author":"Efthimia","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bone.2016.01.011_bb0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jcp.22.3.287","article-title":"The urinary calcium\u2013creatinine ratio as a measure of urinary calcium excretion","volume":"22","author":"Wills","year":"1969","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bone.2016.01.011_bb0065","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1373\/clinchem.2005.049742","article-title":"Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review","volume":"51","author":"Price","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bone.2016.01.011_bb0070","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1002\/jbmr.2266","article-title":"Thalassemia bone disease: a 19-year longitudinal analysis","volume":"29","author":"Wong","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.01.011_bb0075","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00198-013-2454-y","article-title":"The effect of gonadal status on body composition and bone mineral density in transfusion-dependent thalassemia","volume":"25","author":"Wong","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2016.01.011_bb0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0168-8227(02)00025-6","article-title":"The Australian diabetes, obesity and lifestyle study (AusDiab) \u2014 methods and response rates","volume":"57","author":"Dunstan","year":"2002","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.bone.2016.01.011_bb0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000287238","article-title":"Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox","volume":"123","author":"Economou","year":"2010","journal-title":"Acta Haematol."},{"key":"10.1016\/j.bone.2016.01.011_bb0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2141.2010.08477.x","article-title":"Renal dysfunction in patients with thalassaemia","volume":"153","author":"Quinn","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2016.01.011_bb0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1600-0609.2012.01819.x","article-title":"Renal aspects of thalassaemia a changing paradigm","volume":"89","author":"Bhandari","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2016.01.011_bb0100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/abbi.2001.2671","article-title":"The role of heme and iron\u2013sulfur clusters in mitochondrial biogenesis, maintenance, and decay with age","volume":"397","author":"Atamna","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bone.2016.01.011_bb0105","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3324\/haematol.2014.104463","article-title":"Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels","volume":"99","author":"Rossi","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2016.01.011_bb0110","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/ajh.23844","article-title":"Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with beta-thalassemia major","volume":"89","author":"Casale","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bone.2016.01.011_bb0115","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00277-013-1833-y","article-title":"Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters","volume":"93","author":"Ricchi","year":"2014","journal-title":"Ann. Hematol."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216000120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216000120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T22:57:15Z","timestamp":1537052235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216000120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":23,"alternative-id":["S8756328216000120"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.01.011","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}